RYAH Group’s (CSE: RYAH) wholly owned subsidiary, RYAH Medtech Inc., has completed initial shipment of its proprietary Smart Dose-Measuring inhalers for use in a pilot study conducted by CLINN medical center in Milan, Italy. Per the update, CLINN, the first and only cannabis-specialized clinic in Italy, named the best cannabis clinic in Europe by CanEx, is launching an observation study using RYAH devices in order to collect accurate patient feedback on consumption of cannabis strains available on the Italian market. Italy, with 30% growth over the last year, remains the second-largest market in Europe with more than 20,000 patients, which makes it a priority market for RYAH Group. “We are delighted to bring RYAH Medtech’s Smart Inhaler to the CLINN network and support CLINN in integrating their data collection software,” said RYAH’s European Business Development Manager Andrea Ferrari. “The combination of dose-control and data analytics with CLINN’s extensive acumen in plant-based medicine research will set a new standard in cannabis therapies in Italy.”
To view the full press release, visit https://ibn.fm/BPpTU
RYAH Group Inc.
RYAH is a big data and technology company focused on valuable predictive analysis in the global medical intake industry. The company manages a complete digital ecosystem leveraging both internet of things (“IoT”) and artificial intelligence (“AI”) to create a dynamic data service for the medical plant industry. It is developing a suite of IoT devices, including a dry-herb vaporizer device capable of storing all plant lab results, measuring patient inhalation sessions in real-time and capturing instant feedback for plant dose management. Its robust artificial intelligence platform aggregates and correlates HIPAA-compliant medical data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is also relevant for pharmacies, clinics, growers, dispensaries, and licensed processors (“LPs”) to monitor and manage plant strain effects on patients. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete medical plant lifecycle, from seed to consumption. For more information about the company, please visit www.RYAHGroup.com.
NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.